Category : Clinical Intelligence/Clinical Efficiency

Multiple Phase 2 studies of allosteric TYK2 inhibitor in 2021 and 2022 will investigate ‘pipeline-in-a-product’ potential – Financing will also support first-in-human trial of HPK1...

Funding from the COVID-19 Therapeutics Accelerator to advance Exscientia’s novel class of AI-designed coronavirus SARS-CoV-2 Mpro inhibitors to development candidates Exscientia has received a grant from...

The innovative RTSM leader grew over 100% in 2020, plans to accelerate global expansion and support critical demand for products and services 4G Clinical, a...

Addition of technology to save clinicians hours manually documenting quality measurement data Apervita, the trusted platform for healthcare collaboration, today announced that it has added Carta Healthcare’s artificial...

Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development...

Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its...

Lyndra Therapeutics, a clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, today announced the...

Agreement provides NCCA sites access to VIPER™ and other Deep Lens services to improve clinical trial recruitment efficiency Partnership will also expand clinical trial offering to...

Nucleai (www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science...

Longwood Fund-founded company has raised over $70 million since its Q4 2020 launch Proprietary platform licensed from Dr. Stephen Elledge’s laboratory used to develop novel...